INTEGRATED FILING — NBFC



General information about company

Scrip code 533259
NSE Symbol HEALTHX
MSEI Symbol NOTLISTED
ISIN INE019J01013
Name of company HEALTH X PLATFORM LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 14-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Financial Services
Start date and time of board meeting 14-11-2026   12:30:00
End date and time of board meeting 14-11-2026   14:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 14-02-2025
Indicate Company website link for updated RPT policy of the Company https://healthxplatform.com/Pdf/SVL_Related_Party_Transaction_Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default on loan and debt securities.


Financial Results — NBFC

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations
(i) Interest Income 7.25 15.25
(ii) Dividend Income 0.00 0.00
(iii) Rental Income 0.00 0.00
(iv) Fees and commission Income 0.00 0.00
(v) Net gain on fair value changes 0.00 0.00
(vi) Net gain on derecognition of financial instruments under amortised cost category 0.00 0.00
(vii) Sale of products (including Excise Duty) 0.00 0.00
(viii) Sale of services 0.00 0.00
(ix) Other revenue from operations
Total other revenue from operations
Total Revenue From Operations 7.25 15.25
Other income 1.36 2.65
Total income 8.61 17.90
2 Expenses
Cost of materials consumed 0.00 0.00
Purchases of stock-in-trade 0.00 0.00
Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
Employee benefit expense 8.24 16.50
Finance costs 0.00 0.00
Depreciation, depletion and amortisation expense 2.19 4.35
Fees and commission expense 0.00 0.00
Net loss on fair value changes 0.00 0.00
Net loss on derecognition of financial instruments under amortised cost category 0.00 0.00
Impairment on financial instruments 0.00 0.00
(f) Other expenses
1 Other Expenses 30.03 80.33
Total other expenses 30.03 80.33
Total expenses 40.46 101.18
3 Total profit before exceptional items and tax (31.85) (83.28)
4 Exceptional items 0.00 0.00
5 Total profit before tax (31.85) (83.28)
7 Tax expense
8 Current tax 0.00 0.00
9 Deferred tax 0.00 0.00
10 Total tax expenses 0.00 0.00
11 Net Profit Loss for the period from continuing operations (31.85) (83.28)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
17 Net profit (loss) from discontinued operation after tax 0.00 0.00
14 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
15 Total profit (loss) for period (31.85) (83.28)
16 Other comprehensive income net of taxes (0.45) (0.27)
17 Total Comprehensive Income for the period (32.30) (83.55)
18 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
19 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
20 Details of equity share capital
Paid-up equity share capital 3,181.05 3,181.05
Face value of equity share capital 10 10
21 Reserves excluding revaluation reserve
22 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings per share from continuing operations -0.1 -0.26
Diluted earnings per share from continuing operations -0.1 -0.26
ii Earnings per equity share for discontinued operations
Basic earnings per share from discontinued operations 0 0
Diluted earnings per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings per share -0.1 -0.26
Diluted earnings per share -0.1 -0.26
23 Debt equity ratio
24 Debt service coverage ratio
25 Interest service coverage ratio
26 Disclosure of notes on financial results Textual Information(1)


Remarks

23 Debt equity ratio
24 Debt service coverage ratio
25 Interest service coverage ratio


Text Block

Textual Information(1) 1. The above Unaudited Financial Results for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 14, 2026. The Limited review for the quarter and half year ended September 30, 2026 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. 2. The Company being a Core Investment Company has only one reportable business segment and operates in only one geographical segment i.e. within India. 3. The Board of Directors at its meeting held on June 10, 2026, approved a Composite Scheme of Arrangement and Amalgamation (“Scheme”) amongst Health X Platform Limited (“Health X” or “Demerged Company” or “Transferee Company”), Microsec Resources Private Limited (“MRPL” or “Resulting Company” or “Amalgamated Company”), Innogrow Technologies Limited (“ITL” or “Amalgamating Company”) and Sastasundar Healthbuddy Limited (“SHBL” or “Transferor Company”) (collectively referred to as “Companies”) and their respective shareholders and creditors pursuant to Section 230 to 232 and all other applicable provisions of the Companies Act, 2013 and the rules framed thereunder, with effect from April 01, 2026 (“the Appointed Date”). The Scheme is subject to the requisite approvals. Pending such aforesaid approvals, no accounting effect in respect of the proposed Scheme has been given in the financial results for the half year ended September 30, 2026. However, during the previous quarter ended June 30, 2026, the Company has incurred expenses of Rs. 14.75 lakhs in connection with the proposed Scheme, which have been included under Other Expenses in these financial results.


Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (83.28)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories 0.00
Adjustments for decrease (increase) in trade receivables, current 0.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (10.12)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 52.00
Adjustments for other financial assets, current 26.13
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 8.06
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (0.93)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 4.35
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.12
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.08
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.09
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (0.74)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 78.86
Net cash flows from (used in) operations (4.42)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 0.93
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (5.35)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 0.24
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 73.40
Purchase of other long-term assets 72.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities 1.16
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 0.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4.19)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (4.19)
Cash and cash equivalents cash flow statement at beginning of period 5.36
Cash and cash equivalents cash flow statement at end of period 1.17




Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Finanical Asset
Cash and cash equivalents 1.17
Bank Balance other than (a) above 2.57
Derivative financial instruments
Receivables
(I) Trade Receivables
(II) Other Receivables
Loans 320.00
Investments 26,464.91
Other Financial assets
1 Other financial assets 10.47
Total of Other Financial assets 10.47
Total Financial Assets 26,799.12
2 Non Financial Asset
Inventories 0.00
Current tax assets (Net) 19.60
Deferred tax Assets (Net)
Investment Property
Biological assets other than bearer plants
Property, Plant and Equipment 171.40
Capital work-in-progress
Intangible assets under development
Goodwill 0.00
Other Intangible assets 0.00
Other non-financial assets
1 Other Non-Financial assets 33.00
2 Assets held for sale 2.65
Total of Other non-financial assets 35.65
Total Non Financial Assets 226.65
Total assets 27,025.77
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,181.05
Other equity 23,821.55
Total equity attributable to owners of parent 27,002.60
Non controlling interest
Total equity 27,002.60
2 Liabilities
2.1 Financial Liabilities
(a) Derivative financial instruments
(b) Payables
(I)Trade Payables
(i) total outstanding dues of micro enterprises and small enterprises
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises 12.42
II) Other Payables
(i) total outstanding dues of micro enterprises and small enterprises
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises
(C ) Debt Securities
(d) Borrowings (Other than Debt Securities) 0.00
(e) Deposits
(f) Subordinated Liabilities
Other financial liabilities
1 Other financial liabilities 0.48
Total of Other financial liabilities 0.48
Total Financial Liabilities 12.90
2.2 Non-Financial Liabilities
(a) Current tax liabilities (Net)
(b) Provisions 0.00
(C ) Deferred tax liabilities (Net)
Other non-financial liabilities
1 Other Non- Financial Liabilities 10.27
Total of Other non-financial liabilities 10.27
Total Non Financial Liabilities 10.27
Total liabilities 23.17
Total equity and liabilites 27,025.77
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments


Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gain/loss on defined benefit plans (net of tax) -45000 -27000
Total Amount of items that will not be reclassified to profit and loss -45000 -27000
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (0.45) (0.27)




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Health X Platform Limited (formerly Sastasundar Ventures Limited) Pratap Singh Key Management Personnel Remuneration As approved by Nomination and Remuneration Committee 12.04 (0.40) (0.35)
2 Health X Platform Limited (formerly Sastasundar Ventures Limited) Anjana Dikshit Key Management Personnel Any other transaction Director's Sitting Fees As approved by the Board 1.71 0.00 0.00
3 Health X Platform Limited (formerly Sastasundar Ventures Limited) Rupanjana De Key Management Personnel Any other transaction Director's Sitting Fees As approved by the Board 1.82 0.00 0.00
4 Health X Platform Limited (formerly Sastasundar Ventures Limited) Jayanta Nath Mukhopadhyaya Key Management Personnel Any other transaction Director's Sitting Fees As approved by the Board 1.71 0.00 0.00
5 Health X Platform Limited (formerly Sastasundar Ventures Limited) Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Rental & Maintainence Income 4.00 Approval by Audit Committee 1.82 0.00 0.00
6 Health X Platform Limited (formerly Sastasundar Ventures Limited) Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Electricity Charges Reimbursement At Actual 0.06 0.00 0.00
7 Health X Platform Limited (formerly Sastasundar Ventures Limited) Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Corporate Guarantee Utilised 5,850.00 Approval by Audit Committee 2,510.77 0.00 0.00
8 Health X Platform Limited (formerly Sastasundar Ventures Limited) Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Reimbursement of Expenses At Actual 0.00 0.01 0.02
9 Health X Platform Limited (formerly Sastasundar Ventures Limited) Microsec Resources Private Limited Wholly Owned Subsidiary Company Any other transaction Loan Given 600.00 NA 320.00 405.84 327.70 Loan 9.00 3 years Unsecured for its business requirements
10 Health X Platform Limited (formerly Sastasundar Ventures Limited) Microsec Resources Private Limited Wholly Owned Subsidiary Company Any other transaction Refund of Loan Given NA 372.00 0.00 0.00
11 Health X Platform Limited (formerly Sastasundar Ventures Limited) Microsec Resources Private Limited Wholly Owned Subsidiary Company Any other transaction Interest Income Received NA 41.39 0.00 0.00
12 Health X Platform Limited (formerly Sastasundar Ventures Limited) Microsec Resources Private Limited Wholly Owned Subsidiary Company Any other transaction Interest Income NA 15.25 0.00 0.00
13 Microsec Resources Private Limited Myjoy Technologies Private Limited Wholly Owned Subsidiary Companies Any other transaction Loan Given 500.00 NA 37.85 28.79 25.78 Loan 9.00 3 years Unsecured to meet day to day activities & working capital requirement Textual Information(1)
14 Microsec Resources Private Limited Myjoy Technologies Private Limited Wholly Owned Subsidiary Companies Any other transaction Loan Refunded NA 38.85 0.00 0.00 Textual Information(2)
15 Microsec Resources Private Limited Myjoy Technologies Private Limited Wholly Owned Subsidiary Companies Any other transaction Interest Income Received NA 3.27 0.00 0.00 Textual Information(3)
16 Microsec Resources Private Limited Myjoy Technologies Private Limited Wholly Owned Subsidiary Companies Any other transaction Interest Income NA 1.26 0.00 0.00 Textual Information(4)
17 Microsec Resources Private Limited Vikash Somani Key Management Personnel Any other transaction Loan Given NA 10.00 0.00 0.00
18 Microsec Resources Private Limited Vikash Somani Key Management Personnel Any other transaction Interest Income NA 0.04 0.00 10.04
19 Microsec Resources Private Limited Sanjay Agarwal Key Management Personnel Any other transaction Loan Given NA 0.00 3.20 3.30
20 Microsec Resources Private Limited Sanjay Agarwal Key Management Personnel Any other transaction Interest Income NA 0.15 0.00 0.00
21 Microsec Resources Private Limited Sanjay Agarwal Key Management Personnel Any other transaction Interest Income Received NA 0.05 0.00 0.00
22 Microsec Wealth Management Limited Microsec Resources Private Limited Wholly Owned Subsidiary Company Any other transaction Employee Acquisition Adjustment NA 2.92 0.00 2.92 Textual Information(5)
23 Microsec Wealth Management Limited Naveen Vyas Key Management Personnel Remuneration NA 9.40 0.00 (3.45)
24 Microsec Wealth Management Limited Ajay Jaiswal Key Management Personnel Remuneration NA 14.62 0.00 0.00
25 Microsec Wealth Management Limited Sanjay Agarwal Key Management Personnel Remuneration NA 5.40 (0.17) (0.50)
26 Innogrow Technologies Limited Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Rental & Maintainence Income 200.00 NA 89.15 3.10 0.00
27 Innogrow Technologies Limited Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Security Deposit Received At Actual 1,017.69 0.00 (1,017.69)
28 Innogrow Technologies Limited Sastasundar Healthbuddy Limited Subsidiary Companies Any other transaction Electricity Charges Reimbursement Received At Actual 19.60 0.00 0.00
29 Innogrow Technologies Limited TreeCampus Academy Foundation Enterprises on which Key Management Personnel exercise significant influence Any other transaction Charity and Donations 13.00 NA 13.00 0.00 0.00
30 Innogrow Technologies Limited Ginteja Fintech Private Limited Enterprises on which Key Management Personnel exercise significant influence Any other transaction Rental Income 0.48 NA 0.24 0.00 0.00
31 Bharatiya Sanskriti Village Private Limited Ruchika Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) in Limited Liability Partnership 99.00 NA (0.45) 0.00 0.00
32 Bharatiya Sanskriti Village Private Limited Ruchika Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Refund of Investment in Limited Liability Partnership 99.00 NA 2.40 0.00 0.00
33 Bharatiya Sanskriti Village Private Limited Ruchika Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Investment in Limited Liability Partnership NA 0.00 931.17 928.32
34 Bharatiya Sanskriti Village Private Limited Alokik Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) in Limited Liability Partnership 99.00 NA (0.03) 0.00 0.00
35 Bharatiya Sanskriti Village Private Limited Alokik Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Refund of Investment in Limited Liability Partnership 99.00 NA 0.17 0.27 0.07
36 Bharatiya Sanskriti Village Private Limited Dreamscape Advisors LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) in Limited Liability Partnership 99.00 NA (0.05) 0.00 0.00
37 Bharatiya Sanskriti Village Private Limited Dreamscape Advisors LLP LLP in which Subsidiary is Partner Any other transaction Refund of Payables to Limited Liability Partnership NA 0.17 0.00 0.00
38 Bharatiya Sanskriti Village Private Limited Dreamscape Advisors LLP LLP in which Subsidiary is Partner Any other transaction Investment in Limited Liability Partnership NA 0.00 0.30 0.08
39 Bharatiya Sanskriti Village Private Limited Microsec Invictus Advisors LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) in Limited Liability Partnership 99.00 NA 0.00 0.00 0.00
40 Bharatiya Sanskriti Village Private Limited Microsec Invictus Advisors LLP LLP in which Subsidiary is Partner Any other transaction Refund of Investment in Limited Liability Partnership 99.00 NA 0.14 0.24 0.10
41 Bharatiya Sanskriti Village Private Limited Stuti Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) in Limited Liability Partnership 99.00 NA (0.01) 0.00 0.00
42 Bharatiya Sanskriti Village Private Limited Stuti Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Refund of Investment in Limited Liability Partnership 99.00 NA 0.62 0.00 0.00
43 Bharatiya Sanskriti Village Private Limited Stuti Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Investment in Limited Liability Partnership NA 0.16 0.55 0.08
44 Myjoy Technologies Private Limited Alokik Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Investment in LLP NA 2.97 139.00 136.35
45 Myjoy Technologies Private Limited Alokik Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Refund of Investment in Limited Liability Partnership 99.00 NA 3.00 0.00 0.00
46 Myjoy Technologies Private Limited Alokik Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) From LLP 99.00 NA (2.62) 0.00 0.00
47 Myjoy Technologies Private Limited Dreamscape Advisors LLP LLP in which Subsidiary is Partner Any other transaction Investment in LLP NA 6.67 110.68 112.56
48 Myjoy Technologies Private Limited Dreamscape Advisors LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) From LLP 99.00 NA (4.79) 0.00 0.00
49 Myjoy Technologies Private Limited Microsec Invictus Advisors LLP LLP in which Subsidiary is Partner Any other transaction Investment in LLP NA 0.24 0.22 0.20
50 Myjoy Technologies Private Limited Microsec Invictus Advisors LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) From LLP 99.00 NA (0.26) 0.00 0.00
51 Myjoy Technologies Private Limited Ruchika Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Investment in LLP NA 4.80 47.68 52.48
52 Myjoy Technologies Private Limited Ruchika Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Refund of Investment in Limited Liability Partnership 99.00 NA 0.00 0.00 0.00
53 Myjoy Technologies Private Limited Ruchika Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) From LLP 99.00 NA 0.00 0.00 0.00
54 Myjoy Technologies Private Limited Stuti Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Investment in LLP NA 1.99 23.86 24.63
55 Myjoy Technologies Private Limited Stuti Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Refund of Payables to LLP NA 0.00 0.00 0.00
56 Myjoy Technologies Private Limited Stuti Advisory Services LLP LLP in which Subsidiary is Partner Any other transaction Share of Profit/(Loss) From LLP 99.00 NA (1.22) 0.00 0.00
57 Sastasundar Healthbuddy Limited Sastasundar Healthtech Private Limited Subsidiary Companies Any other transaction Re-imbursement towards expenses NA 1.12 0.00 0.00
58 Sastasundar Healthbuddy Limited Genu Path Labs Limited Subsidiary Companies Any other transaction Investment in Equity Shares NA 70.00 0.00 0.00
59 Sastasundar Healthbuddy Limited Mitsubishi Corporation India Private Limited Enterprise exercising significant influence over the Company Any other transaction Re-imbursement towards expenses NA 80.31 0.00 0.00
60 Sastasundar Healthbuddy Limited Rupanjana De Key Management Personnel Any other transaction Director's Sitting Fees NA 1.16 0.00 0.00
61 Sastasundar Healthbuddy Limited Jayanta Nath Mukhopadhyaya Key Management Personnel Any other transaction Director's Sitting Fees NA 1.65 0.00 0.00
62 Sastasundar Healthbuddy Limited Anjana Dikshit Key Management Personnel Any other transaction Director's Sitting Fees NA 0.50 0.00 0.00
63 Sastasundar Healthbuddy Limited Banwari Lal Mittal Key Management Personnel Remuneration NA 102.59 0.00 0.00
64 Sastasundar Healthbuddy Limited Ramesh Kumar Sharma Key Management Personnel Remuneration NA 21.94 0.00 (4.89)
65 Sastasundar Healthbuddy Limited Lokesh Agarwal Key Management Personnel Remuneration NA 29.30 0.00 (4.88)
66 Sastasundar Healthbuddy Limited Nilabh Vishnu Key Management Personnel Remuneration NA 9.20 0.00 (1.54)
67 Sastasundar Healthbuddy Limited Lokesh Agarwal Key Management Personnel Any other transaction Re-imbursement for expenses NA 0.15 0.00 0.00
68 Sastasundar Healthbuddy Limited Nilabh Vishnu Key Management Personnel Any other transaction Re-imbursement for expenses NA 0.10 0.00 0.00
69 Sastasundar Healthbuddy Limited Ramesh Kumar Sharma Key Management Personnel Any other transaction Re-imbursement for expenses NA 0.10 0.00 0.00
70 Genu Path Labs Limited Sastasundar Healthtech Private Limited Associate company Any other transaction Commission NA 1.98 (2.55) (0.18)
71 Genu Path Labs Limited Parimal Kumar Chattaraj Key Management Personnel Any other transaction Director's Sitting Fees NA 0.40 0.00 0.00
72 Genu Path Labs Limited Paritosh Nandi Key Management Personnel Any other transaction Director's Sitting Fees NA 0.40 0.00 0.00
73 Genu Path Labs Limited Bhaskar Bhattacharya Key Management Personnel Remuneration NA 17.80 0.00 (2.97)
74 Genu Path Labs Limited Bhaskar Bhattacharya Key Management Personnel Any other transaction Professional Fees NA 0.01 0.00 0.00
75 Genu Path Labs Limited Bhaskar Bhattacharya Key Management Personnel Any other transaction Reimbursement of Expense NA 0.03 0.00 0.00
76 Genu Path Labs Limited Banwari Lal Mittal Key Management Personnel Sale of goods or services NA 0.32 0.00 0.00
77 Genu Path Labs Limited Ravi Kant Sharma Key Management Personnel Sale of goods or services NA 0.04 0.00 0.00
78 Genu Path Labs Limited Nilabh Vishnu Key Management Personnel Sale of goods or services NA 0.04 0.00 0.00
79 Genu Path Labs Limited Lokesh Agarwal Key Management Personnel of Holding Company Sale of goods or services NA 0.02 0.00 0.00
80 Genu Path Labs Limited Others Relatives of Key Management Personnel Sale of goods or services NA 0.50 0.00 0.00
Total value of transaction during the reporting period 4,895.62



Text Block

Textual Information(1) the transactions of the wholly owned subsidiaries of the listed entity and amongst the wholly owned subsidiaries are exempt as per the provisions of Regulation 23.
Textual Information(2) the transactions of the wholly owned subsidiaries of the listed entity and amongst the wholly owned subsidiaries are exempt as per the provisions of Regulation 23.
Textual Information(3) the transactions of the wholly owned subsidiaries of the listed entity and amongst the wholly owned subsidiaries are exempt as per the provisions of Regulation 23.
Textual Information(4) the transactions of the wholly owned subsidiaries of the listed entity and amongst the wholly owned subsidiaries are exempt as per the provisions of Regulation 23.
Textual Information(5) the transactions of the wholly owned subsidiaries of the listed entity and amongst the wholly owned subsidiaries are exempt as per the provisions of Regulation 23.